Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATCell for Post-Concussion Syndrome
NCT04744051Phase 1Unknown
- Sponsor
- American CryoStem Corporation
- Start
- Feb 2021
- Primary completion
- Sep 2023
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of astrostem in Post-concussion syndrome (PCS) (4 arms), sponsored by American CryoStem Corporation. Primary endpoints: Health Status using the 36 item Short Form Health Survey at 6 months, Assessment of Visual Attention and Task Switching at 6 months and 9 more. Status: unknown.
02
Drugs
astrostem
03
Conditions
Post-concussion syndrome (PCS)
Beyond the preview
Go deeper on NCT04744051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744051.